Skip to Content

Posts tagged with "Business and Markets"

  • Business and Markets

    Go Home, Gaijin

    Too many foreigners in your drug company? Outsiders being put into positions of power and influence, threatening the entire firm’s culture? That’s the objection that many Takeda employees seem to have to the company’s recent tendency (unusual in Japan, to say the least) of bringing in many non-Japanese hires at all levels. The Fin… Read More
  • Business and Markets

    Rearrangements Inside Bristol-Myers Squibb

    I’ve heard from more than one source that BMS has been moving people around (and in some cases, out) in several departments recently. As a whole, the company has been doing quite well, but (as many have found out) that’s no guarantee that you won’t be re-orgged. From what I’ve heard, this isn’t the major… Read More
  • Business and Markets

    Valeant’s Misleading Case

    Matthew Herper has excellent coverage here of Valeant’s bid for Allergan, specifically Valeant’s view of actual pharma R&D (which they, for the most part, don’t bother to do). He’s especially peeved (with reason) that the company is citing some of his own stories on the topic of R&D productivity to make its case, b… Read More
  • Business and Markets

    Nutley Demolished

    For those who worked at, visited, or remember the Hoffman-LaRoche site in Nutley, here’s what the end of the line looks like. After closing it as an R&D facility, the company is now putting five of the buildings on the market, and tearing down the rest. The remaining buildings look to be picked up by… Read More
  • Business and Markets

    Valuing Biotech Startups

    Via Bruce Booth on Twitter, here’s an in-depth look at the financing of small biotechs, compared to the financing of internet and IT-centric startups. As everyone knows, many of the latter companies are able to raise staggering amounts of money, far more than the best-funded biotech startups have ever seen. But the comparisons across financin… Read More
  • Business and Markets

    Sanofi’s Feeling Just Wonderful

    Chris Viehbacher of Sanofi has an interview with reporters from Bloomberg, where he says some interesting things. Such as “Unlike everybody else, we feel we’ve got critical mass in all of our businesses” and “. . .at today’s prices I don’t see anything that I can acquire that strengthens our company and creates value for… Read More
  • Business and Markets

    Pharmalot Returns

    I’m glad to report that Ed Silverman has revived the Pharmalot blog, now at the Wall Street Journal. This is the third iteration, and I’m glad to see that it’s as unkillable as it appears to be! Read More
  • Business and Markets

    How to Buy, Buy, Buy

    I really got a kick out of “The Seven Deadly Sins of Biotech Investing“, sent to Adam Feuerstein by one of his readers. It’s a sort of Screwtape Letters/Devil’s Dictionary look at the sector, with gems of wisdom like this: Find a good Internet message board to discuss how great an investment the biotech stock… Read More
  • Business and Markets

    AstraZeneca Survives

    So Pfizer has officially called off their quest to acquire AstraZeneca. I didn’t expect things to end like this – up until now, what Pfizer has wanted, Pfizer has gotten (well, except in the clinic). There may well have been other behind-the-scenes overtures that we never heard about being rejected over the years, but this… Read More
  • Business and Markets

    Two Looks At Drug Industry Productivity

    Matthew Herper has a really interesting story in Forbes on a new report that attempts to rank biopharma companies by their R&D abilities. Richard Evans of Sector and Sovereign Health (ex-Roche) has ranked companies not on their number of drugs, but on their early-stage innovation. He counts patents, for example, but not the later ones… Read More
...282930...